Volume 10, Issue 3 ( September 2018 2018)                   Iranian Journal of Blood and Cancer 2018, 10(3): 82-86 | Back to browse issues page

XML Print


1- Guilan University of Medical Sciences
2- Guilan Blood Transfusion Organization
3- Guilan University of Medical Sciences , shakib@gums.ac.ir
Abstract:   (4055 Views)

Background: Advances in treatment of thalassemia major (TM) have improved life expectancy and survival of the patients. This study was conducted to assess survival rate of these patients in Guilan province, Northern Iran.
Methods: In this cross-sectional study, records of 1243 patients with TM from 2001 to March 2016 were evaluated in Guilan province. Sources of data were health centers of the province and territories, blood transfusion organization, general hospitals and private clinics. Data were analyzed using Kaplan–Meier method. 
Results: 958 (77%) patients were born before 1997, the year that screening program of β-thalassemia in Iran was started. No case of β-TM was born during the last 5 years of the study. The 5, 10, and 15-year survival rate for all patients were 100%, 100%, and 99.6%, respectively. Hepatitis C infection was associated with decreased survival rate.
Conclusion: Survival in patients with TM has dramatically improved over the recent years and future studies about causes of death in these patients are highly recommended.

Full-Text [PDF 501 kb]   (2259 Downloads)    
: Original Article | Subject: Pediatric Hematology & Oncology
Received: 2018/07/26 | Accepted: 2018/09/15 | Published: 2018/10/24

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.